A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and...

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Chronic inflammation is linked to cancer development, presenting a significant clinical challenge.
• Epigenetic dysregulation is a key factor in inflammation and cancer.
• Epigenetic-modulating compounds are increasingly used in clinical settings.

Purpose of the Study:

• To evaluate the anti-inflammatory and anti-cancer properties of a novel quinazoline epigenetic modulator.
• To explore the compound's effects on gene expression in prostate cancer cell lines.
• To identify affected biological pathways and networks.

Main Methods:

• Utilized a non-hypothesis-driven transcriptomics approach with Affymetrix PrimeView® Human Gene Expression microarray.
• Analyzed gene expression data from PC3 and DU145 prostate cancer cell lines.
• Employed GATHER and IPA software for pathway and network analysis.

Main Results:

• Identified differentially expressed genes in both prostate cancer cell lines.
• Top canonical pathways affected included cholesterol biosynthesis, metabolism, and the mevalonate pathway.
• Observed significant modifications in biological processes, pathways, and networks.

Conclusions:

• The quinazoline compound exhibits anti-inflammatory and anti-cancer effects in prostate cancer models.
• Targeting sterol and mevalonate pathways represents a promising anti-cancer strategy.
• Epigenetic modulation offers a potential avenue for cancer therapy.